FDA
-
-
-
-
-
-
-
FDA approves Genentech's Venclexta plus acalabrutinib for CLL treatment
-
-
-
-
-
-
-
FDA Approves Genentech’s Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma
-
-
-
-
-
-
-
Genentech’s Tecentriq Showed Significant Overall and Disease-Free Survival Benefits in Bladder Cancer With ctDNA-Guided Treatment
-
-
-
-
-
-
-
FDA approves Genentech's Tecentriq plus lurbinectedin for lung cancer
-
-
-
-
-
-
-
Genentech and Roche Present New Insights in Alzheimer’s Disease Research Across Its Diagnostics and Pharmaceutical Portfolios at AAIC
-
-
-
-
-
-
-
Genentech’s Tecentriq Combined with Lurbinectedin Shows Significant Survival Benefit in Extensive-Stage Small Cell Lung Cancer
-
-
-
-
-
-
-
New England Journal of Medicine Publishes Phase III Data Showing Single-dose Xofluza Significantly Reduces Influenza Virus Transmission
-
327,748 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

